Next-Generation
Protein Conjugation
At CatenaBio, we envision a future where therapeutics are limited only by imagination.
Because sometimes biology isn’t enough.
Building with biologics should be as easy as building with small molecules.
Today, we can't make the medicines we’d like to, because current approaches to building biologic structures are limited.
About CatenaBioImagine if you could:
Breakthrough Protein Conjugation
CatenaBio’s CysTyr™ platform utilizes the novel Catenase™ enzyme, which catalyzes the formation of our proprietary C-Y Bond™ using only native amino acids.
Our approach eliminates the current size and complexity constraints that restrict molecule connections. This allows attachment of multiple different cargoes to a protein, delivering new therapeutic modalities.
All this is accomplished with greater speed, stability, selectivity, and scalability than current approaches.
Explore the science
Our approach eliminates the current size and complexity constraints that restrict molecule connections. This allows attachment of multiple different cargoes to a protein, delivering new therapeutic modalities.
All this is accomplished with greater speed, stability, selectivity, and scalability than current approaches.
Explore the science
Exceptional Minds
Exceptional Innovation
Our team has been instrumental in advancing medical research. Our technology was developed in the same halls where CRISPR was born, a connection that fuels our passion for pushing the boundaries of scientific discovery.
Meet our team
Our Pipeline:
Transforming the ADC Market Through Revolutionary
Multi-Payload Conjugate™ Technology
View our pipeline
CatenaBio Presents Poster on Multi-Payload Conjugates at the American Association for Cancer Research (AACR) Annual Meeting
April 8, 2024 San Diego, CA